When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
CRMD - NGM Bio Aldafermin Data And Other News: The Good Bad And Ugly Of Biopharma
CorMedix Inc.
NGM Bio reports positive Phase 2 data for Aldafermin
NGM Biopharmaceuticals Inc. (NGM) reported final data from its 24-week Phase 2 study of aldafermin 1 mg. The trial involved patients with non-alcoholic steatohepatitis. The readout included a new analysis of data gathered from Cohort 4 consisting of NASH patients with stage 3 liver fibrosis. The company also reported that it has completed enrolment for its ongoing Phase 2b ALPINE 2/3 study.
The data from Phase 2 trial of aldafermin 1 mg showed that the drug candidate had a potent anti-fibrotic impact on NASH